|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Baehner FL et al. Quantitative RT-PCR analysis of ER and PR by Oncotype DX™ indicates distinct and different associations with prognosis and prediction of tamoxifen benefit. San Antonio Breast Cancer Symposium 2006;Abstract 45.
Boccardo F et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d’Utilisation (ATU). Proc ASCO 2008;Abstract 1094.
Lin NU et al. Lapatinib and capecitabine for the treatment of brain metastases in patients with HER2+ breast cancer — An updated analysis from EGF105084. Poster. San Antonio Breast Cancer Symposium 2007;Abstract 6076.
Martin M et al. Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing TAC with FAC: 5-year efficacy analysis of the GEICAM 9805 trial. Proc ASCO 2008;Abstract 542.
O’Shaughnessy J et al. A randomized study of lapatinib in combination with trastuzumab versus lapatinib monotherapy in heavily pretreated HER2+ metastatic breast cancer patients progressing on trastuzumab therapy. Proc ASCO 2008;Abstract 1015.
 |
 |
EDITOR
Neil Love, MD
INTERVIEWS
Nancy E Davidson, MD
- Select publications
Professor John Crown, MD
- Select publications
Kathy D Miller, MD
- Select publications
Peter M Ravdin, MD, PhD
- Select publications
THREE PERSPECTIVES ON US COOPERATIVE GROUP RESEARCH
Norman Wolmark, MD
- Select publications
Joyce O’Shaughnessy, MD
- Select publications
Eric P Winer, MD
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
